A1M Pharma’s leading research and development work within preeclampsia, a disorder that affects ten million pregnant women each year, will be featured in an episode of the TV show Innovations with Ed Begley Jr., broadcasted on Fox Business in the US. The episode featuring A1M Pharma is scheduled to air during the third quarter of 2017.

“I am looking forward to this possibility to further raise the awareness of preeclampsia and A1M Pharma’s development of the candidate drug ROSGardTM as a future treatment. We also expect that our clinical program within treatment of preeclampsia and protection against kidney damage in connection with radiation therapy, where a safety study in healthy volunteers is scheduled to start in the beginning of 2018, will attract more attention among international investors in countries such as the US”, says A1M Pharma’s CEO Tomas Eriksson.

The TV show Innovations with Ed Begley Jr. highlights advances within a number of industries, such as health and wellness, renewable energy, technology, global business and more. The show is hosted by the actor and environmentalist Ed Begley, Jr., and is produced by DMG Productions, LLC. For more information about the show, visit www.Innovationstelevision.com.

For more information, please contact
Tomas Eriksson, CEO
Telephone: +46 46-286 50 30
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

About A1M Pharma
Several preclinical studies indicate that A1M Pharma’s candidate drug, ROSGard™, based on the endogenous protein Alpha-1-Microglobulin, restores impairments to kidney function by repairing damaged tissue and protecting against oxidative stress. Kidney injury is a condition which often occurs in connection with preeclampsia and which often limits the possibilities of using radiation therapies as a treatment for cancer. The company’s two indications are kidney protection in connection with Peptide Receptor Radionuclide Therapy (PRRT) – a targeted radiation therapy for cancer – with the aim of opening the possibility of increasing treatment levels and so fight metastatic cancer more effectively as well as treatment of preeclampsia. Every year, over 12 million people are affected by acute kidney injuries that can lead to permanent kidney damage. Preeclampsia affects around 10 million pregnant women worldwide and is responsible for 76,000 maternal and 500,000 infant deaths each year. A1M Pharma is listed on Nasdaq First North Stockholm since 20 June 2017. A1M Pharma’s Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00.
A1M Pharma AB | Scheelevägen 22 | 223 63 Lund
+46 46 286 50 30 | info@a1m.se
Medlem av Preeclampsia Foundation
Legal disclaimer | © Copyright - A1M